~9 spots leftby Mar 2026

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Recruiting in Palo Alto (17 mi)
+2 other locations
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Taiho Oncology, Inc.
No Placebo Group
Breakthrough Therapy

Trial Summary

What is the purpose of this trial?Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.

Eligibility Criteria

Participant Groups

1Treatment groups
Experimental Treatment
Group I: Futibitanib in combination with binimetinibExperimental Treatment1 Intervention
Dose escalation: Futibitanib in combination with binimetinib in patients with advanced cancer disease. Dose expansion: Futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC
Binimetinib is already approved in United States, European Union, Canada, Japan for the following indications:
🇺🇸 Approved in United States as Mektovi for:
  • Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
🇪🇺 Approved in European Union as Mektovi for:
  • Unresectable or metastatic melanoma with a BRAF V600 mutation
🇨🇦 Approved in Canada as Mektovi for:
  • Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
🇯🇵 Approved in Japan as Mektovi for:
  • Unresectable or metastatic melanoma with a BRAF V600 mutation

Find A Clinic Near You

Research locations nearbySelect from list below to view details:
University of California Los Angeles UCLA CancerSanta Monica, CA
Community Cancer Center NorthIndianapolis, IN
The University of Texas MD Anderson Cancer CenterHouston, TX
Loading ...

Who is running the clinical trial?

Taiho Oncology, Inc.Lead Sponsor

References